Clinical Trial

A Study of BGM0504 in Early T2DM With Obesity

Name: A Study of BGM0504 in Early T2DM With Obesity — clinical trial record (NCT07743983)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.

Trial Details

NCT Number	NCT07743983
Lead Sponsor	BrightGene Bio-Medical Technology Co., Ltd.
Conditions	Type 2 Diabetes (T2DM)
Enrollment	372 participants
Start Date	2026-08-30
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-04